The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Safety and early activity of SL-401 plus pomalidomide in R/R multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of using SL-401, a plasmacytoid dendritic cell-targeting antibody, in combination with pomalidomide as a novel strategy for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). Dr Richardson highlights the safety and early activity of this approach and notes that the next step is to develop this platform further. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
There was a recent publication from our team regarding the use of pomalidomide and SL-401, which is a plasmacytoid dendritic cell targeting antibody, which is going into early studies. I appreciated you asking me about that because the data there show that that’s a safe approach and very active. It’s been the practical application of it. Why we’re kind of very interested in it is targeting plasmacytoid dendritic cells may have a role in the setting of immune therapies including CAR-T, because we’re realizing that when CAR-T fails a patient there are various things that happen and one of them appears to be a very pivotal role from these types of cells, these plasmacytoid dendritic cells appear to have a role in relapse...
There was a recent publication from our team regarding the use of pomalidomide and SL-401, which is a plasmacytoid dendritic cell targeting antibody, which is going into early studies. I appreciated you asking me about that because the data there show that that’s a safe approach and very active. It’s been the practical application of it. Why we’re kind of very interested in it is targeting plasmacytoid dendritic cells may have a role in the setting of immune therapies including CAR-T, because we’re realizing that when CAR-T fails a patient there are various things that happen and one of them appears to be a very pivotal role from these types of cells, these plasmacytoid dendritic cells appear to have a role in relapse. So one can think theoretically at least about strategies combining SL-401 with immunomodulatory drugs and being able to take that forward as a strategy between immune treatments. But obviously our primary role with our work was, is this a safe platform to develop? We showed that it was active. The question now is how would we then take it forward?
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Celgene/Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron, Sanofi: Consultancy; Oncopeptides: Research Funding.
